GLP-1 Drugs and Your Kidneys: Protective Over Years, Risky Over Days

The answer to “is this bad for my kidneys” is that it depends entirely on the timescale. Over years, in people who already have chronic kidney disease, semaglutide reduced the risk of kidney failure, a large drop in kidney function, or death from kidney or cardiovascular causes by 24%.^[1] Over days, the label warns about acute kidney injury — in some reported cases requiring dialysis — in people who become dehydrated from vomiting or diarrhea.^[3] Both are real, and the second is the one you can do something about this week.

The long-run picture

FLOW enrolled 3,533 people carrying two diagnoses at once — type 2 diabetes, and kidney disease already established — assigning them semaglutide or placebo and following them a median of 3.4 years.^[1] Its primary outcome bundled the things that actually matter in kidney disease: kidney failure, a sustained fall of half or more in filtration rate, and death from kidney or cardiovascular causes.

That last row is the one nephrologists look at. Kidney function declines with time in this population; a treatment that flattens the slope buys years before dialysis becomes the conversation. Our FLOW trial page sets the study out in full.

The short-run warning

Now the other half, which appears in Section 5.5 of the label rather than in any trial headline. Since the drug reached the market, cases of sudden kidney injury have been reported in people taking semaglutide — some severe enough that dialysis was needed. The label is specific about the pattern: the majority occurred in patients who had gastrointestinal reactions leading to dehydration — nausea, vomiting, diarrhea.^[3]

The mechanism is not the drug reaching the kidney. It is you not reaching a glass of water.

That distinction matters because it changes what to do. A drug that damaged kidneys directly would be a reason to avoid it in kidney disease. A drug that occasionally causes enough vomiting to dehydrate someone is a reason to take dehydration seriously — which is manageable, and which the same label asks prescribers to monitor.

What the systematic review adds

A 2025 Cochrane review assessed the benefits and harms of GLP-1 drugs across people with chronic kidney disease and diabetes at every stage from 1 to 5, with death, major cardiovascular events, kidney failure and severe hypoglycemia among its primary outcomes.^[2] Cochrane reviews are the most conservative form of synthesis there is — they weight risk of bias heavily and are reliably reluctant to overstate.

The value of having one here is less about any single number and more about the class having been examined at that standard at all. A conclusion that survives Cochrane’s methodology is a different kind of claim from one built on a manufacturer-funded trial alone, and FLOW was funded by Novo Nordisk.

Reconciling the two halves

• Having chronic kidney disease is not a reason to avoid these drugs. In the population that has it, the trial evidence points the other way entirely.
• The acute risk is downstream of the gastrointestinal effects, which are worst during dose escalation. That is when to be most careful about fluids, and our water intake calculator and side-effect timeline cover the window.
• Kidney function is measurable, which puts this among the few risks on this site where you can simply ask for the number. If you have kidney disease or take drugs that affect the kidneys, ask what is being monitored and how often.
• Dose-stacking and compounded vials complicate this, because the gastrointestinal effects scale with dose and an unverified concentration makes the dose uncertain — see what is in a compounded vial.